33658t Search Results


a salmonicida type strain atcc 33658t  (ATCC)
96
ATCC a salmonicida type strain atcc 33658t
A Salmonicida Type Strain Atcc 33658t, supplied by ATCC, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/33658t/Aeromonas+salmonicida+subsp%2E+salmonicida+(Lehmann+and+Neumann)+Griffen+et+al/us07351550-282-1-5
Average 96 stars, based on 1 article reviews
a salmonicida type strain atcc 33658t - by Bioz Stars, 2026-08
96/100 stars
  Buy from Supplier
33656t vpi 0990 gcf 000020605 1 complete  (ATCC)
93
ATCC 33656t vpi 0990 gcf 000020605 1 complete
33656t Vpi 0990 Gcf 000020605 1 Complete, supplied by ATCC, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/33658t/Leptospira+noguchii+Yasuda+et+al/pmc11019791__msystems__01401___23___s0009-3-3-2
Average 93 stars, based on 1 article reviews
33656t vpi 0990 gcf 000020605 1 complete - by Bioz Stars, 2026-08
93/100 stars
  Buy from Supplier
atcc 33658  (ATCC)
95
ATCC atcc 33658
Atcc 33658, supplied by ATCC, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/33658t/Aeromonas+salmonicida%3B+subsp%2E+salmonicida/pmc10526069-107-13-13
Average 95 stars, based on 1 article reviews
atcc 33658 - by Bioz Stars, 2026-08
95/100 stars
  Buy from Supplier
antibody against nedd9  (Santa Cruz Biotechnology)
92
Santa Cruz Biotechnology antibody against nedd9
Figure 4. Loss of <t>NEDD9</t> or inhibition of BCL-XL renders PIK3CA-mutant gastric cancer cells hypersensitive to BYL719 treatment by increasing cell-cycle arrest and cell death, respectively. A, Western blot of NEDD9 expression in parental and NEDD9-knockout AGS cells. B, GI50 curve of BYL719 in parental and NEDD9-knockout AGS cells measured by CellTiter Glo at 3 days. C, Representative BrdU plots of AGS parental and NEDD9-knockout cells treated with either DMSO or 2 mmol/L BYL719 for 24 hours. D, Reduction in S phase in parental and NEDD9-knockout AGS cells after 24 hours of treatment with 2 mmol/L BYL719. E, Increase in cells in G0–G1 and G2–M phase after 24 hours of treatment with 2 mmol/L BYL719. F, GI50 curve of BYL719 only and the addition of 500 nmol/L A-1331852 measured by CellTiter Glo at 3 days. G, Cells were treated with 1 mmol/L BYL719 or 500 nmol/L A-1331852 alone and in combination. Cell viability was measured by Trypan Blue exclusion after 3 days. H, Cells were treated with 1 mmol/L BYL719 or 500 nmol/L A-1331852 alone and in combination. After 24 hours, cellswere harvested and stained for activated caspase- 3 for flow cytometry. For all, error bars show mean SEM. For experiments in B, F, and H; n ¼ 3. For experiments in D and E, n ¼ 5. For experiments in G; n ¼ 6; , P < 0.05; , P < 0.01; , P < 0.005; , P < 0.001.
Antibody Against Nedd9, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/33658t/Cas-L+Antibody/10__1158_slash_1541___7786__mcr___23___0034-118-0-9
Average 92 stars, based on 1 article reviews
antibody against nedd9 - by Bioz Stars, 2026-08
92/100 stars
  Buy from Supplier
aeromonas salmonicida ncimb 1102  (NCIMB Ltd)
90
NCIMB Ltd aeromonas salmonicida ncimb 1102
Figure 4. Loss of <t>NEDD9</t> or inhibition of BCL-XL renders PIK3CA-mutant gastric cancer cells hypersensitive to BYL719 treatment by increasing cell-cycle arrest and cell death, respectively. A, Western blot of NEDD9 expression in parental and NEDD9-knockout AGS cells. B, GI50 curve of BYL719 in parental and NEDD9-knockout AGS cells measured by CellTiter Glo at 3 days. C, Representative BrdU plots of AGS parental and NEDD9-knockout cells treated with either DMSO or 2 mmol/L BYL719 for 24 hours. D, Reduction in S phase in parental and NEDD9-knockout AGS cells after 24 hours of treatment with 2 mmol/L BYL719. E, Increase in cells in G0–G1 and G2–M phase after 24 hours of treatment with 2 mmol/L BYL719. F, GI50 curve of BYL719 only and the addition of 500 nmol/L A-1331852 measured by CellTiter Glo at 3 days. G, Cells were treated with 1 mmol/L BYL719 or 500 nmol/L A-1331852 alone and in combination. Cell viability was measured by Trypan Blue exclusion after 3 days. H, Cells were treated with 1 mmol/L BYL719 or 500 nmol/L A-1331852 alone and in combination. After 24 hours, cellswere harvested and stained for activated caspase- 3 for flow cytometry. For all, error bars show mean SEM. For experiments in B, F, and H; n ¼ 3. For experiments in D and E, n ¼ 5. For experiments in G; n ¼ 6; , P < 0.05; , P < 0.01; , P < 0.005; , P < 0.001.
Aeromonas Salmonicida Ncimb 1102, supplied by NCIMB Ltd, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/33658t/a++salmonicida+ncimb+1102/pm23324417-39-10-14
Average 90 stars, based on 1 article reviews
aeromonas salmonicida ncimb 1102 - by Bioz Stars, 2026-08
90/100 stars
  Buy from Supplier
spoilage organisms  (ATCC)
93
ATCC spoilage organisms
Figure 4. Loss of <t>NEDD9</t> or inhibition of BCL-XL renders PIK3CA-mutant gastric cancer cells hypersensitive to BYL719 treatment by increasing cell-cycle arrest and cell death, respectively. A, Western blot of NEDD9 expression in parental and NEDD9-knockout AGS cells. B, GI50 curve of BYL719 in parental and NEDD9-knockout AGS cells measured by CellTiter Glo at 3 days. C, Representative BrdU plots of AGS parental and NEDD9-knockout cells treated with either DMSO or 2 mmol/L BYL719 for 24 hours. D, Reduction in S phase in parental and NEDD9-knockout AGS cells after 24 hours of treatment with 2 mmol/L BYL719. E, Increase in cells in G0–G1 and G2–M phase after 24 hours of treatment with 2 mmol/L BYL719. F, GI50 curve of BYL719 only and the addition of 500 nmol/L A-1331852 measured by CellTiter Glo at 3 days. G, Cells were treated with 1 mmol/L BYL719 or 500 nmol/L A-1331852 alone and in combination. Cell viability was measured by Trypan Blue exclusion after 3 days. H, Cells were treated with 1 mmol/L BYL719 or 500 nmol/L A-1331852 alone and in combination. After 24 hours, cellswere harvested and stained for activated caspase- 3 for flow cytometry. For all, error bars show mean SEM. For experiments in B, F, and H; n ¼ 3. For experiments in D and E, n ¼ 5. For experiments in G; n ¼ 6; , P < 0.05; , P < 0.01; , P < 0.005; , P < 0.001.
Spoilage Organisms, supplied by ATCC, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/33658t/Shewanella+algae/pm40005614-51-8-12
Average 93 stars, based on 1 article reviews
spoilage organisms - by Bioz Stars, 2026-08
93/100 stars
  Buy from Supplier
vibrio mimicus atcc 33653t  (ATCC)
93
ATCC vibrio mimicus atcc 33653t
Figure 4. Loss of <t>NEDD9</t> or inhibition of BCL-XL renders PIK3CA-mutant gastric cancer cells hypersensitive to BYL719 treatment by increasing cell-cycle arrest and cell death, respectively. A, Western blot of NEDD9 expression in parental and NEDD9-knockout AGS cells. B, GI50 curve of BYL719 in parental and NEDD9-knockout AGS cells measured by CellTiter Glo at 3 days. C, Representative BrdU plots of AGS parental and NEDD9-knockout cells treated with either DMSO or 2 mmol/L BYL719 for 24 hours. D, Reduction in S phase in parental and NEDD9-knockout AGS cells after 24 hours of treatment with 2 mmol/L BYL719. E, Increase in cells in G0–G1 and G2–M phase after 24 hours of treatment with 2 mmol/L BYL719. F, GI50 curve of BYL719 only and the addition of 500 nmol/L A-1331852 measured by CellTiter Glo at 3 days. G, Cells were treated with 1 mmol/L BYL719 or 500 nmol/L A-1331852 alone and in combination. Cell viability was measured by Trypan Blue exclusion after 3 days. H, Cells were treated with 1 mmol/L BYL719 or 500 nmol/L A-1331852 alone and in combination. After 24 hours, cellswere harvested and stained for activated caspase- 3 for flow cytometry. For all, error bars show mean SEM. For experiments in B, F, and H; n ¼ 3. For experiments in D and E, n ¼ 5. For experiments in G; n ¼ 6; , P < 0.05; , P < 0.01; , P < 0.005; , P < 0.001.
Vibrio Mimicus Atcc 33653t, supplied by ATCC, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/33658t/Vibrio+mimicus+Davis+et+al/10__1128_slash_aem__00712___11-63-35-37
Average 93 stars, based on 1 article reviews
vibrio mimicus atcc 33653t - by Bioz Stars, 2026-08
93/100 stars
  Buy from Supplier
e rectale atcc 33656t  (ATCC)
93
ATCC e rectale atcc 33656t
Figure 4. Loss of <t>NEDD9</t> or inhibition of BCL-XL renders PIK3CA-mutant gastric cancer cells hypersensitive to BYL719 treatment by increasing cell-cycle arrest and cell death, respectively. A, Western blot of NEDD9 expression in parental and NEDD9-knockout AGS cells. B, GI50 curve of BYL719 in parental and NEDD9-knockout AGS cells measured by CellTiter Glo at 3 days. C, Representative BrdU plots of AGS parental and NEDD9-knockout cells treated with either DMSO or 2 mmol/L BYL719 for 24 hours. D, Reduction in S phase in parental and NEDD9-knockout AGS cells after 24 hours of treatment with 2 mmol/L BYL719. E, Increase in cells in G0–G1 and G2–M phase after 24 hours of treatment with 2 mmol/L BYL719. F, GI50 curve of BYL719 only and the addition of 500 nmol/L A-1331852 measured by CellTiter Glo at 3 days. G, Cells were treated with 1 mmol/L BYL719 or 500 nmol/L A-1331852 alone and in combination. Cell viability was measured by Trypan Blue exclusion after 3 days. H, Cells were treated with 1 mmol/L BYL719 or 500 nmol/L A-1331852 alone and in combination. After 24 hours, cellswere harvested and stained for activated caspase- 3 for flow cytometry. For all, error bars show mean SEM. For experiments in B, F, and H; n ¼ 3. For experiments in D and E, n ¼ 5. For experiments in G; n ¼ 6; , P < 0.05; , P < 0.01; , P < 0.005; , P < 0.001.
E Rectale Atcc 33656t, supplied by ATCC, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/33658t/Pseudomonas+aeruginosa/10__1128_slash_jb__05637___11-46-12-14
Average 93 stars, based on 1 article reviews
e rectale atcc 33656t - by Bioz Stars, 2026-08
93/100 stars
  Buy from Supplier
33658t  (ATCC)
99
ATCC 33658t
Figure 4. Loss of <t>NEDD9</t> or inhibition of BCL-XL renders PIK3CA-mutant gastric cancer cells hypersensitive to BYL719 treatment by increasing cell-cycle arrest and cell death, respectively. A, Western blot of NEDD9 expression in parental and NEDD9-knockout AGS cells. B, GI50 curve of BYL719 in parental and NEDD9-knockout AGS cells measured by CellTiter Glo at 3 days. C, Representative BrdU plots of AGS parental and NEDD9-knockout cells treated with either DMSO or 2 mmol/L BYL719 for 24 hours. D, Reduction in S phase in parental and NEDD9-knockout AGS cells after 24 hours of treatment with 2 mmol/L BYL719. E, Increase in cells in G0–G1 and G2–M phase after 24 hours of treatment with 2 mmol/L BYL719. F, GI50 curve of BYL719 only and the addition of 500 nmol/L A-1331852 measured by CellTiter Glo at 3 days. G, Cells were treated with 1 mmol/L BYL719 or 500 nmol/L A-1331852 alone and in combination. Cell viability was measured by Trypan Blue exclusion after 3 days. H, Cells were treated with 1 mmol/L BYL719 or 500 nmol/L A-1331852 alone and in combination. After 24 hours, cellswere harvested and stained for activated caspase- 3 for flow cytometry. For all, error bars show mean SEM. For experiments in B, F, and H; n ¼ 3. For experiments in D and E, n ¼ 5. For experiments in G; n ¼ 6; , P < 0.05; , P < 0.01; , P < 0.005; , P < 0.001.
33658t, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/33658t/Bacteria/10__1128_slash_jcm__41__8__3854___3856__2003-98-11-10
Average 99 stars, based on 1 article reviews
33658t - by Bioz Stars, 2026-08
99/100 stars
  Buy from Supplier
a salmonicida hg3 atcc 33658tb united kingdom fish  (ATCC)
94
ATCC a salmonicida hg3 atcc 33658tb united kingdom fish
Figure 4. Loss of <t>NEDD9</t> or inhibition of BCL-XL renders PIK3CA-mutant gastric cancer cells hypersensitive to BYL719 treatment by increasing cell-cycle arrest and cell death, respectively. A, Western blot of NEDD9 expression in parental and NEDD9-knockout AGS cells. B, GI50 curve of BYL719 in parental and NEDD9-knockout AGS cells measured by CellTiter Glo at 3 days. C, Representative BrdU plots of AGS parental and NEDD9-knockout cells treated with either DMSO or 2 mmol/L BYL719 for 24 hours. D, Reduction in S phase in parental and NEDD9-knockout AGS cells after 24 hours of treatment with 2 mmol/L BYL719. E, Increase in cells in G0–G1 and G2–M phase after 24 hours of treatment with 2 mmol/L BYL719. F, GI50 curve of BYL719 only and the addition of 500 nmol/L A-1331852 measured by CellTiter Glo at 3 days. G, Cells were treated with 1 mmol/L BYL719 or 500 nmol/L A-1331852 alone and in combination. Cell viability was measured by Trypan Blue exclusion after 3 days. H, Cells were treated with 1 mmol/L BYL719 or 500 nmol/L A-1331852 alone and in combination. After 24 hours, cellswere harvested and stained for activated caspase- 3 for flow cytometry. For all, error bars show mean SEM. For experiments in B, F, and H; n ¼ 3. For experiments in D and E, n ¼ 5. For experiments in G; n ¼ 6; , P < 0.05; , P < 0.01; , P < 0.005; , P < 0.001.
A Salmonicida Hg3 Atcc 33658tb United Kingdom Fish, supplied by ATCC, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/33658t/Enterococcus+faecalis+(Andrewes+and+Horder)+Schleifer+and+Kilpper-Balz/10__1128_slash_aem__01357___09-97-213-216
Average 94 stars, based on 1 article reviews
a salmonicida hg3 atcc 33658tb united kingdom fish - by Bioz Stars, 2026-08
94/100 stars
  Buy from Supplier
agathobacter rectalis  (ATCC)
96
ATCC agathobacter rectalis
Figure 4. Loss of <t>NEDD9</t> or inhibition of BCL-XL renders PIK3CA-mutant gastric cancer cells hypersensitive to BYL719 treatment by increasing cell-cycle arrest and cell death, respectively. A, Western blot of NEDD9 expression in parental and NEDD9-knockout AGS cells. B, GI50 curve of BYL719 in parental and NEDD9-knockout AGS cells measured by CellTiter Glo at 3 days. C, Representative BrdU plots of AGS parental and NEDD9-knockout cells treated with either DMSO or 2 mmol/L BYL719 for 24 hours. D, Reduction in S phase in parental and NEDD9-knockout AGS cells after 24 hours of treatment with 2 mmol/L BYL719. E, Increase in cells in G0–G1 and G2–M phase after 24 hours of treatment with 2 mmol/L BYL719. F, GI50 curve of BYL719 only and the addition of 500 nmol/L A-1331852 measured by CellTiter Glo at 3 days. G, Cells were treated with 1 mmol/L BYL719 or 500 nmol/L A-1331852 alone and in combination. Cell viability was measured by Trypan Blue exclusion after 3 days. H, Cells were treated with 1 mmol/L BYL719 or 500 nmol/L A-1331852 alone and in combination. After 24 hours, cellswere harvested and stained for activated caspase- 3 for flow cytometry. For all, error bars show mean SEM. For experiments in B, F, and H; n ¼ 3. For experiments in D and E, n ¼ 5. For experiments in G; n ¼ 6; , P < 0.05; , P < 0.01; , P < 0.005; , P < 0.001.
Agathobacter Rectalis, supplied by ATCC, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/33658t/Eubacterium+rectale/pm41240073-39-47-51
Average 96 stars, based on 1 article reviews
agathobacter rectalis - by Bioz Stars, 2026-08
96/100 stars
  Buy from Supplier
aeromonas salmonicida subsp  (ATCC)
93
ATCC aeromonas salmonicida subsp
Figure 4. Loss of <t>NEDD9</t> or inhibition of BCL-XL renders PIK3CA-mutant gastric cancer cells hypersensitive to BYL719 treatment by increasing cell-cycle arrest and cell death, respectively. A, Western blot of NEDD9 expression in parental and NEDD9-knockout AGS cells. B, GI50 curve of BYL719 in parental and NEDD9-knockout AGS cells measured by CellTiter Glo at 3 days. C, Representative BrdU plots of AGS parental and NEDD9-knockout cells treated with either DMSO or 2 mmol/L BYL719 for 24 hours. D, Reduction in S phase in parental and NEDD9-knockout AGS cells after 24 hours of treatment with 2 mmol/L BYL719. E, Increase in cells in G0–G1 and G2–M phase after 24 hours of treatment with 2 mmol/L BYL719. F, GI50 curve of BYL719 only and the addition of 500 nmol/L A-1331852 measured by CellTiter Glo at 3 days. G, Cells were treated with 1 mmol/L BYL719 or 500 nmol/L A-1331852 alone and in combination. Cell viability was measured by Trypan Blue exclusion after 3 days. H, Cells were treated with 1 mmol/L BYL719 or 500 nmol/L A-1331852 alone and in combination. After 24 hours, cellswere harvested and stained for activated caspase- 3 for flow cytometry. For all, error bars show mean SEM. For experiments in B, F, and H; n ¼ 3. For experiments in D and E, n ¼ 5. For experiments in G; n ¼ 6; , P < 0.05; , P < 0.01; , P < 0.005; , P < 0.001.
Aeromonas Salmonicida Subsp, supplied by ATCC, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/33658t/Scopulariopsis+brevicaulis/pmc08388650-150-10-13
Average 93 stars, based on 1 article reviews
aeromonas salmonicida subsp - by Bioz Stars, 2026-08
93/100 stars
  Buy from Supplier

Image Search Results


Figure 4. Loss of NEDD9 or inhibition of BCL-XL renders PIK3CA-mutant gastric cancer cells hypersensitive to BYL719 treatment by increasing cell-cycle arrest and cell death, respectively. A, Western blot of NEDD9 expression in parental and NEDD9-knockout AGS cells. B, GI50 curve of BYL719 in parental and NEDD9-knockout AGS cells measured by CellTiter Glo at 3 days. C, Representative BrdU plots of AGS parental and NEDD9-knockout cells treated with either DMSO or 2 mmol/L BYL719 for 24 hours. D, Reduction in S phase in parental and NEDD9-knockout AGS cells after 24 hours of treatment with 2 mmol/L BYL719. E, Increase in cells in G0–G1 and G2–M phase after 24 hours of treatment with 2 mmol/L BYL719. F, GI50 curve of BYL719 only and the addition of 500 nmol/L A-1331852 measured by CellTiter Glo at 3 days. G, Cells were treated with 1 mmol/L BYL719 or 500 nmol/L A-1331852 alone and in combination. Cell viability was measured by Trypan Blue exclusion after 3 days. H, Cells were treated with 1 mmol/L BYL719 or 500 nmol/L A-1331852 alone and in combination. After 24 hours, cellswere harvested and stained for activated caspase- 3 for flow cytometry. For all, error bars show mean SEM. For experiments in B, F, and H; n ¼ 3. For experiments in D and E, n ¼ 5. For experiments in G; n ¼ 6; , P < 0.05; , P < 0.01; , P < 0.005; , P < 0.001.

Journal: Molecular Cancer Research

Article Title: CBF-Beta Mitigates PI3K-Alpha–Specific Inhibitor Killing through PIM1 in PIK3CA-Mutant Gastric Cancer

doi: 10.1158/1541-7786.mcr-23-0034

Figure Lengend Snippet: Figure 4. Loss of NEDD9 or inhibition of BCL-XL renders PIK3CA-mutant gastric cancer cells hypersensitive to BYL719 treatment by increasing cell-cycle arrest and cell death, respectively. A, Western blot of NEDD9 expression in parental and NEDD9-knockout AGS cells. B, GI50 curve of BYL719 in parental and NEDD9-knockout AGS cells measured by CellTiter Glo at 3 days. C, Representative BrdU plots of AGS parental and NEDD9-knockout cells treated with either DMSO or 2 mmol/L BYL719 for 24 hours. D, Reduction in S phase in parental and NEDD9-knockout AGS cells after 24 hours of treatment with 2 mmol/L BYL719. E, Increase in cells in G0–G1 and G2–M phase after 24 hours of treatment with 2 mmol/L BYL719. F, GI50 curve of BYL719 only and the addition of 500 nmol/L A-1331852 measured by CellTiter Glo at 3 days. G, Cells were treated with 1 mmol/L BYL719 or 500 nmol/L A-1331852 alone and in combination. Cell viability was measured by Trypan Blue exclusion after 3 days. H, Cells were treated with 1 mmol/L BYL719 or 500 nmol/L A-1331852 alone and in combination. After 24 hours, cellswere harvested and stained for activated caspase- 3 for flow cytometry. For all, error bars show mean SEM. For experiments in B, F, and H; n ¼ 3. For experiments in D and E, n ¼ 5. For experiments in G; n ¼ 6; , P < 0.05; , P < 0.01; , P < 0.005; , P < 0.001.

Article Snippet: Antibody against NEDD9 (Cas-L 2G9; sc-33659) was purchased from Santa Cruz Biotechnology.

Techniques: Inhibition, Mutagenesis, Western Blot, Expressing, Knock-Out, Staining, Cytometry